EX-10.29 3 w20549a3exv10w29.htm EX-10.29Exclusive Manufacturing and Supply Agreement • May 5th, 2020
Exhibit 10.29 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT This RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made this 24th day of June 2005 (the “Effective Date”), by and among Sucampo Pharma Europe Ltd., a corporation organized and existing under the laws of United Kingdom and having its principal office at 78 Cannon Street, London EC4N6NQ, United Kingdom (“SPE”), and R-Tech Ueno Ltd., a corporation organized and existing under the laws of Japan and having its principal office at 1-1-7 Uchisaiwai-cyo, Chiyoda-ku, Tokyo 100-0011, Japan (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”). WHEREAS, SPE and RTU executed the Basic Exclusive Supply Agreement Term Sheet dated March 30, 2005 (the “Term Sheet”), which sets forth the basic terms and conditions under which RTU shall manufacture and supply certa
ContractExclusive Manufacturing and Supply Agreement • May 5th, 2020 • New York
EX-10.1 2 exh_101.htm EXHIBIT 10.1 EXHIBIT 10.1 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT THIS LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT ("Agreement") is made this 1st day of January 2014 (the "Effective Date"), by and between Sucampo AG, a corporation organized and existing under the laws of Switzerland, and having its principal office at Baarerstrasse 22, 6300 Zug, Switzerland ("SAG"), and R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, Japan ("RTU") (each referred to herein as a "Party" and collectively as the "Parties"). WHEREAS, the affiliates of SAG have entered into the following manufacturing and supply agreements with RTU for Lubiprostone (also known as RU-0211, SPI-0211, and AMITIZA®): 1) RU-
= Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of The Securities Exchange Act of 1934, as amended. Unoprostone Exclusive Manufacturing and...Exclusive Manufacturing and Supply Agreement • May 11th, 2009 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS UNOPROSTONE EXCLUSIVE MANUFACTURING AND SUPPY AGREEMENT (“Agreement”) is made this 23 day of April, 2009 (the “Effective Date”), by and among Sucampo Pharma Americas, Inc., (“SPA”) a corporation organized and existing under the laws of the State of Delaware, U.S.A., (and a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A.), and having its principal office at 4520 East West Highway, Third Floor, Bethesda, Maryland 20814, and R Tech Ueno, Ltd., (“RTU”) a corporation organized and existing under the laws of Japan and having its registered office at Uchisaiwai-cho 1-1-7, Chiyoda-ku, Tokyo, Japan, 100-0011 (each referred to herein as a “Party” and collectively as the “Parties”).
LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTExclusive Manufacturing and Supply Agreement • March 16th, 2009 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made this 23th day of February, 2009 (the “Effective Date”), by and among Sucampo Pharma, Ltd., a corporation organized and existing under the laws of Japan and a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, U.S.A., and having its principal office at Sakurabashi Toyo Building, Fourth Floor, 2-2-16 Sonezakishinchi, Kita-ku, Osaka 530-0002 (“SPL”), R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011 (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”).
EXHIBIT 10.1Exclusive Manufacturing and Supply Agreement • October 9th, 1997 • North American Scientific Inc • In vitro & in vivo diagnostic substances • Delaware
Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTExclusive Manufacturing and Supply Agreement • October 25th, 2006 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS RU-0211 EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made this 23rd day of June 2004 (the “Effective Date”), by and among Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, U.S.A. and having its principal office at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814, U.S.A. (“SPI”), and the Pharma Chemical division (formally Sucampo Pharma Manufacturing Division) (“PCD”) of R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at 4-1, Techno Park, Sanda, Hyogo, Japan 669-1339 (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”).
EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT THIS AGREEMENT made as of December 18, 1998, between THE HOFFMASTER DIVISION OF THE FONDA GROUP, INC., a Delaware corporation, ("Hoffmaster") and CREATIVE EXPRESSIONS GROUP, INC., a Delaware corporation,...Exclusive Manufacturing and Supply Agreement • February 10th, 1999 • Fonda Group Inc • Paperboard containers & boxes • Wisconsin
ContractExclusive Manufacturing and Supply Agreement • May 7th, 2021 • Axonics, Inc. • Surgical & medical instruments & apparatus • England
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTExclusive Manufacturing and Supply Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT ("Agreement") is made this 1st day of January 2014 (the "Effective Date"), by and between Sucampo AG, a corporation organized and existing under the laws of Switzerland, and having its principal office at Baarerstrasse 22, 6300 Zug, Switzerland ("SAG"), and R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, Japan ("RTU") (each referred to herein as a "Party" and collectively as the "Parties").
